Search research articles
Contact Us
Filters
Showing results (61-70 of 83) with videos related to
Page
of 9
Sort By:
Cancer Medicine
|
March 19, 2024
A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors
Dejan Juric, Minal Barve, Ulka Vaishampayan, et al.
Journal for Immunotherapy of Cancer
|
July 24, 2021
CX-072 (pacmilimab), a Probody <b></b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
Aung Naing, Fiona Thistlethwaite, Elisabeth G E De Vries, et al.
The New England Journal of Medicine
|
May 6, 2026
Daraxonrasib in Previously Treated Advanced <i>RAS</i>-Mutated Pancreatic Cancer
Brian M Wolpin, Wungki Park, Ignacio Garrido-Laguna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 16, 2015
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
George D Demetri, Margaret von Mehren, Robin L Jones, et al.
Cancer Treatment and Research Communications
|
July 30, 2021
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer
Emiliano Calvo, Alexander Spira, María de Miguel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2008
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
Lecia V Sequist, Renato G Martins, David Spigel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2021
Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement
Edward S Kim, Thomas S Uldrick, Caroline Schenkel, et al.
The Lancet. Oncology
|
December 17, 2013
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
Charles Butts, Mark A Socinski, Paul L Mitchell, et al.
JAMA
|
April 8, 2020
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial
William D Tap, Andrew J Wagner, Patrick Schöffski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 2, 2016
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial
Daniel P Petrylak, Scott T Tagawa, Manish Kohli, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 83) with videos related to
Sort By:
Page
of 9
Cancer Medicine
|
March 19, 2024
A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors
Dejan Juric, Minal Barve, Ulka Vaishampayan, et al.
Journal for Immunotherapy of Cancer
|
July 24, 2021
CX-072 (pacmilimab), a Probody <b></b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
Aung Naing, Fiona Thistlethwaite, Elisabeth G E De Vries, et al.
The New England Journal of Medicine
|
May 6, 2026
Daraxonrasib in Previously Treated Advanced <i>RAS</i>-Mutated Pancreatic Cancer
Brian M Wolpin, Wungki Park, Ignacio Garrido-Laguna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 16, 2015
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
George D Demetri, Margaret von Mehren, Robin L Jones, et al.
Cancer Treatment and Research Communications
|
July 30, 2021
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer
Emiliano Calvo, Alexander Spira, María de Miguel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2008
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
Lecia V Sequist, Renato G Martins, David Spigel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2021
Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement
Edward S Kim, Thomas S Uldrick, Caroline Schenkel, et al.
The Lancet. Oncology
|
December 17, 2013
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
Charles Butts, Mark A Socinski, Paul L Mitchell, et al.
JAMA
|
April 8, 2020
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial
William D Tap, Andrew J Wagner, Patrick Schöffski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 2, 2016
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial
Daniel P Petrylak, Scott T Tagawa, Manish Kohli, et al.
Page
of 9